1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemoswed Holding Reports Financial Results For Third Quarter 2022

MAR

Today, on 9 November 2022, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2022.

Q3 2022 KEY INDICATORS

  • Net sales amounted to 34.1MSEK (32.2)
  • EBITDA equalled 4.8 MSEK (4.9)
  • Operating profit (EBIT) is 1.4 MSEK (1.9)
  • Profit after tax amounted to 1.2 MSEK (1.5)
  • Earnings per share SEK 0,1 (0,1) per share

JAN-SEPT 2022 KEY INDICATORS

  • Net sales amounted to 99.7 MSEK (96.2)
  • EBITDA equalled 18.9 MSEK (12.5)
  • Operating profit (EBIT) is 8.9 MSEK (3.8)
  • Profit after tax amounted to 7.9 MSEK (3.0)
  • Earnings per share SEK 0,7 (0,3) per share

“Magle Group continued to deliver healthy year-on-year growth, both in terms of revenues and operating profit. The EBITDA margin is continuously in line with our financial target of 20%, and we remain well on track to deliver on our long-term strategic goals” says Justin Pierce, CEO of Magle Group.


The full report is available at https://maglegroup.com/financial-reports/

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-09 08:29 CET.

Attachments

Interim Report Q3 2022

Datum 2022-11-09, kl 08:29
Källa MFN
Bifogade filer
Interim Report Q3 2022
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.